CJC-1295 + Ipamorelin
aka Mod GRF 1-29 stack · GHRH + ghrelin mimetic
The most common growth-hormone secretagogue pairing: a GHRH analogue combined with a selective ghrelin-receptor agonist, intended to raise endogenous GH pulses rather than inject exogenous GH.
Mechanism of action
CJC-1295 activates pituitary GHRH receptors to increase pulse amplitude; ipamorelin activates GHS-R1a to increase pulse frequency without meaningfully raising cortisol or prolactin, unlike earlier secretagogues.
Doses used in published studies
Phase I CJC-1295 studies used 30–60 µg/kg single doses. Ipamorelin human data is limited to short postoperative-ileus trials.
These figures describe what researchers administered under supervision. They are reported for accuracy and are not a protocol, recommendation, or substitute for clinical guidance.
Reported benefits
- Dose-dependent increases in GH and IGF-1 in Phase I studies
- Better selectivity profile than GHRP-6 or GHRP-2
- Preserves pulsatile GH physiology versus exogenous rhGH
Risks & unknowns
- Insulin resistance and elevated fasting glucose with sustained IGF-1 elevation
- Water retention, carpal-tunnel symptoms, joint discomfort
- Theoretical proliferation risk in undiagnosed malignancy
- No long-term outcome data in healthy adults
Legal & regulatory status
Both were added to the FDA's 503A Category 2 bulk list in 2023, removing them from legal US compounding. WADA-prohibited (S2). Some GH secretagogues, such as macimorelin, are approved solely as diagnostic agents.
Check status in your state or country →Key studies
- Pharmacokinetics and Pharmacodynamics of CJC-1295 in Healthy Adults
Journal of Clinical Endocrinology & Metabolism · 2006